10-K: VSee Health Reports Massive Loss Amid Restatement & Going Concern Doubts

VSee Health, Inc. reported a net loss of over $57 million for 2024, driven by significant goodwill impairment and financial restatements, raising substantial doubt about its ability to continue as a going concern.

Summary

• VSee Health, Inc. filed its comprehensive Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which includes restated financial statements for 2023 and interim periods of 2023 and 2024.
• The company identified material errors in the recognition and measurement of accrued expenses and revenue transactions, leading to the restatement of previously issued financial statements.
• A net loss of $57,702,015 was reported for the year ended December 31, 2024, a significant increase from the $3,725,454 net loss in 2023.
• Operating expenses surged by 1,115% to $69,328,425 in 2024, primarily due to $56,675,210 in goodwill impairment charges.
• Revenue increased by 81% to $10,421,352 in 2024, driven by the acquisition of iDoc and higher technical/engineering and professional fees.
• The company had an accumulated deficit of $67,703,873 and negative operating cash flows of $5,789,542 as of December 31, 2024.
• Management and auditors have concluded that substantial doubt exists about the company's ability to continue as a going concern.
• VSee Health operates two segments: Healthcare Technology (VSee Lab) offering a comprehensive telehealth platform, and Telehealth Services (iDoc) providing high-acuity patient care solutions.
• The company faces intense competition from established telehealth providers, EMR vendors, large health plans, and major technology companies.
• VSee Health has received notices of non-compliance from Nasdaq for late filings and faces a delisting risk, with a hearing scheduled for September 9, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a massive net loss, negative cash flows, an accumulated deficit, and explicit going concern doubts. Significant financial restatements and material weaknesses in internal controls further erode confidence. While revenue growth is present, it is overshadowed by these critical issues and the risk of Nasdaq delisting. The ongoing need for dilutive financing underscores the precarious financial position.

Positives

• Total revenues increased by 81% to $10,421,352 in 2024, up from $5,765,889 in 2023.
• Revenue growth was driven by the acquisition of iDoc, contributing $2,217,733, and a 201% increase in technical and engineering fees due to new and existing clients.
• Professional and other fees increased by 98% due to higher project management services, patient visits, and hardware purchases.
• The company's telehealth platform (VSee Lab) offers 'no code/low code' configuration, remote physical exam, remote patient monitoring, and AI for telesitter/telenursing solutions.
• iDoc provides specialized intensive care unit services (neurointensivists, cardiac intensivists, medical intensivists) and e-consults to diverse customers, including the federal prison system.
• VSee Health has developed a unique quality control program with hospital-specific reporting dashboards to monitor and improve critical care quality.

Negatives

• Reported a significant net loss of $57,702,015 for the year ended December 31, 2024, a 1,449% increase from the prior year.
• Operating expenses increased by 1,115% to $69,328,425 in 2024, primarily due to $56,675,210 in goodwill impairment charges.
• Accumulated deficit reached $67,703,873 as of December 31, 2024.
• Negative cash flow from operating activities worsened to $5,789,542 in 2024 from $632,595 in 2023.
• Substantial doubt exists about the company's ability to continue as a going concern, as stated by management and independent auditors.
• Identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel, ineffective IT General Controls, and lack of formalized control environment.
• The company is not currently engaged in active research and development spending due to capital constraints, which could hinder future differentiation and growth.
• Received notices of non-compliance from Nasdaq for failure to timely file reports and faces a risk of delisting.
• The company's current cash on hand ($326,115 as of December 31, 2024) is insufficient to meet operating cash needs for the next 12 months.

Risks

• The restatement of previously issued financial statements and associated remedial measures have been time-consuming and expensive, potentially exposing the company to additional risks.
• Uncertainty regarding the company's ability to continue as a going concern due to accumulated deficit, continuing net losses, and negative cash flows.
• Operating in a highly competitive and rapidly evolving telemedicine market, facing competition from established providers, EMR vendors, large health plans, and major technology companies.
• Demand for and market utilization of software and solutions are subject to a high degree of uncertainty, with potential for slow market development or negative publicity.
• Future losses are expected, and the company may never achieve or sustain profitability.
• Long and unpredictable sales cycles require considerable time and expense, making sales, revenues, and cash flows difficult to predict.
• Developments affecting spending by the healthcare industry, including government regulations, consolidation, and economic downturns, could adversely affect revenues.
• Potential medical malpractice risks inherent in providing healthcare services, which could lead to substantial costs and reputational harm.
• Reliance on physician and physician extender abilities, and the ability to maintain and expand the network of board-certified physicians and provider specialists.
• Dependence on relationships with affiliated professional entities to provide medical services, with risks of disruption or violations of corporate practice of medicine prohibitions.
• Failure to develop and release new solutions or enhancements in a timely manner could harm the business.
• Inability to offer high-quality technical support services may harm client relationships and financial results.
• Intense competition for qualified personnel, including highly skilled employees and senior management, could hinder growth.
• Acquisitions of other companies or technologies could divert management's attention, result in dilution, and disrupt operations.
• Failure to manage future growth effectively could lead to unexpected expenses and inability to meet client requirements.
• Inaccurate estimates and assumptions used to determine the total addressable market could affect future growth rates.
• Potential for future litigation, which could be costly and time-consuming to defend.
• Taxing authorities may assert that sales and use, value-added, or similar taxes should have been collected, leading to liability for past or future sales.
• Likely requirement for additional capital from equity or debt financings, which might not be available on acceptable terms or could be dilutive.
• Volatility in the price of common stock and public warrants.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
• The restatement of financial statements may affect investor confidence and raise reputational issues.
• Commitments to issue shares of common stock or convertible securities may cause significant dilution and encourage short sales.
• Risk of delisting from Nasdaq due to non-compliance with listing requirements, leading to reduced liquidity and ability to raise capital.
• Lack of formalized cybersecurity measures, dedicated team, or specific protocols, leaving the company vulnerable to cyberattacks and data breaches.

Future Outlook

Management anticipates continuing operating losses and negative cash flows in the future. Plans to alleviate going concern doubts include raising additional working capital through public or private equity or debt financings, collaborations with third parties, and disciplined cash spending. The company plans to focus future research and development on delivering new products and enhancing existing solutions to maintain market viability and strength.

Management Comments

• Management has concluded that substantial doubt exists about our ability to continue as a going concern for one year after the date our consolidated financial statements are issued.
• We believe that the rapid transformation of the telehealth market indicates strong future growth of the market, and our current offerings provide an attractive value proposition to health systems, medical groups, and individual medical practitioners, driving higher market share.
• We plan to continue to harness our scale to further grow the value proposition of our platform for all stakeholders.
• We believe our ability to invest in new technology and develop new features, modules, and solutions will be critical to our long-term success.
• We lack the resources to employ additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we receive additional funding to support our accounting department.

Industry Context

The company operates in a rapidly transforming and highly competitive telehealth market, characterized by increasing demand for digital patient engagement and solutions to clinician shortages. The growth and evolution of cloud services and technology are enabling more specialized tele-intensive care and telemedicine solutions. However, the market is also seeing consolidation among healthcare providers and increased competition from large, well-financed health plans and technology giants, leading to pricing pressures. The company aims to address physician burnout and lack of patient access to quality intensive care in a post-COVID healthcare system.

Comparison to Industry Standards

• The company's 'no code/low code' approach for clinicians to configure telehealth workflows is presented as a differentiator against more rigid EMR-built telehealth tools and video conferencing software like Zoom and Microsoft Teams.
• VSee's solutions augment video-only telehealth with medical device streaming and monitoring, contrasting with many existing tools limited to video.
• iDoc's focus on optimizing an extensive network of board-certified physicians and highly configurable workflows is highlighted as a competitive advantage against hardware-centric competitors like Hicuity Health, INTELEICU, and enVision teleICU.
• The company acknowledges that major reasons for telehealth solutions not capturing full potential include repurposed non-healthcare specific video/hardware/software, lack of integration for remote monitoring devices, and unoptimized backend software coordination, which VSee aims to address with its technology.

Corporate Governance

Legal Proceedings

• A lawsuit was filed against the company on July 25, 2024, alleging breach of contract and unjust enrichment, with the plaintiffs seeking payment under promissory notes and related to the Encompass Acquisition Agreement.
• The company has filed a counterclaim for breach of contract, promissory estoppel, and unjust enrichment against the plaintiffs.
• Settlement discussions are actively ongoing, but the range of potential loss cannot be reasonably estimated as of December 31, 2024.

Related Party Transactions

• On October 4, 2023, DHAC issued an unsecured promissory note for $165,000 to M2B, an affiliate of the Sponsor, which was paid off on January 31, 2024.
• Loans incurred by VSee Lab and iDoc to the Bridge Investor (an investor in the Sponsor) and Tidewater (a Sponsor Affiliate) totaling $1,785,000 were converted into Common Stock following the Business Combination.
• On December 31, 2024, the company entered into the Ascent Purchase Agreement with Ascent (an affiliate of the Bridge Investor) to issue a $2,000,000 secured convertible promissory note.
• On November 8, 2024, $405,000 in working capital funds advanced by SCS, LLC (a Sponsor affiliate) were converted into 202,500 shares of Common Stock, treated as a troubled debt restructuring.
• On June 21, 2024, a Consulting Services Agreement was entered with SCS, LLC, for $12,500 per month for business consulting and $2,500 per month for remote office space, plus initial and future stock issuances.
• DHAC owed the Sponsor and certain Sponsor affiliates $504,659 in advances for working capital, of which $47,800 was repaid in cash and $405,000 was converted to common stock, leaving $51,900 due as of December 31, 2024.
• Milton Chen (then CEO of VSee Lab) provided promissory notes totaling $320,000 to VSee Lab in 2023, which accrued interest at 12% (26% upon default).
• Imoigele Aisiku (then CEO of iDoc) had a related party balance due from him of $531,656 and a note receivable of $336,000 which was written off in 2024.
• iDoc had a $200,000 promissory note with a board member, with payments based on monthly revenue from telepresence robots.
• David L. Wickersham (a board member) received 114,000 shares of common stock to satisfy a $224,000 secured convertible promissory note from iDoc.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity and convertible debt financings, as well as potential loss of investment due to going concern doubts and Nasdaq delisting risk.
• Employees may experience uncertainty due to the company's financial difficulties and the need for cost-cutting measures, though the company aims to attract and retain skilled personnel.
• Customers may face service disruptions or reduced quality if the company's financial issues impact its ability to invest in technology, support services, or maintain its provider network.
• Creditors face increased risk due to the company's default on certain notes and line of credit, and the overall substantial doubt about its ability to continue as a going concern.
• Regulatory bodies are scrutinizing the company due to financial restatements and material weaknesses in internal controls, potentially leading to further investigations or penalties.

Next Steps

• Remediate material weaknesses in internal control over financial reporting, which requires additional funding for the accounting department.
• Raise additional working capital through public or private equity or debt financings or other sources.
• Engage in collaborations with third parties to support business growth.
• Implement disciplined cash spending measures.
• Focus future research and development on delivering new products and enhancing solutions functionality, performance, and flexibility.
• Attend a hearing before the Nasdaq Hearings Panel on September 9, 2025, to address non-compliance with listing standards and avoid delisting.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements for the year ending December 31, 2025.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, marked by a substantial net loss of over $57 million, primarily due to a massive goodwill impairment. The explicit 'going concern' doubt from both management and auditors, coupled with negative operating cash flows and an accumulated deficit, indicates a high risk of business failure. The significant financial restatements and identified material weaknesses in internal controls point to fundamental operational and governance issues. Furthermore, the company faces imminent Nasdaq delisting risk due to late filings. While revenue growth is noted, it is entirely overshadowed by these critical negatives. The continuous need for dilutive capital raises, often at reset conversion prices, will further erode shareholder value. A seasoned investor would view this as a highly speculative and distressed situation with a strong likelihood of further capital destruction.

Keywords

Telehealth, Telemedicine, Digital Health, Healthcare Technology, Virtual Care, ICU Services, Neurocritical Care, Remote Patient Monitoring, AI in Healthcare, SEC Filing, 10-K, Financial Restatement, Going Concern, Nasdaq Delisting Risk, Healthcare Regulation, HIPAA Compliance, Software as a Service